Pfizer reports 41% drop in revenue for full year 2023

Pfizer has disclosed its financial results for the entire year 2023, which show a fall in revenues of $58.5 billion. This represents a decrease of 41% from the revenue of $100.33 billion that was reported in 2022.

Share This Post

Pfizer announced its 2023 yearly financial figures, showing a substantial decrease in revenue to $58.5 billion, marking a 42% drop from the previous year’s $100.33 billion. This decline was largely due to a decrease in sales of its COVID-19 vaccine, Comirnaty, and the antiviral Paxlovid, alongside a 41% operational decrease and a slight negative impact from foreign exchange rates. However, excluding these COVID-19 related products, the company saw a 7% operational growth.

CFO David Denton expressed satisfaction with the 8% operational growth of non-COVID products in the last quarter, aligning with their annual growth target. Additionally, Pfizer is on course to achieve significant cost savings by the end of 2024 through a cost realignment program. The year ended with a notable decline in earnings per share, emphasizing the impact of reduced COVID-19 product sales.


Share This Post

Transforming Science & Technology into Effective Marketing

Let's Find Out What We Can Do For You​

We add value to scientific and technological businesses by implementing creative marketing tactics to boost sales, align internal teams, and outperform competition in the market.

Latest Market & Industry News

How do we Get in Touch?

Drop Us A Line to connect

Let have a chat about your challenges and how we could help and support you to evolve your marketing strategy and execution. 

Creative marketing_Connect
Creative Marketing Logo

Let's connect

and Find Out How We Can Support Your Business